HUP0401612A2 - Cukorbetegség kezelésére alkalmas gyógyszerkészítmények - Google Patents

Cukorbetegség kezelésére alkalmas gyógyszerkészítmények

Info

Publication number
HUP0401612A2
HUP0401612A2 HU0401612A HUP0401612A HUP0401612A2 HU P0401612 A2 HUP0401612 A2 HU P0401612A2 HU 0401612 A HU0401612 A HU 0401612A HU P0401612 A HUP0401612 A HU P0401612A HU P0401612 A2 HUP0401612 A2 HU P0401612A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
composition suitable
treating diabetes
subject
medicinal product
Prior art date
Application number
HU0401612A
Other languages
English (en)
Inventor
Aaron I. Vinik
Lawrence Rosenberg
Gary Pittenger
David Taylor-Fishwick
Michael Salem
Scott Mohrland
Original Assignee
Gmp Endotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gmp Endotherapeutics Inc. filed Critical Gmp Endotherapeutics Inc.
Publication of HUP0401612A2 publication Critical patent/HUP0401612A2/hu
Publication of HUP0401612A3 publication Critical patent/HUP0401612A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4733—Acute pancreatitis-associated protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A találmány tárgyát emlősszervezetben természetes körülmények közöttelőforduló, Langerhans-sziget neogenezisével társult fehérjébőlszármazó, legalább 15, egymást követő aminosavval rendelkezőpolipeptidet tartalmazó gyógyszerkészítmény képezi. A találmánytárgyát képezi továbbá ezen gyógyszerkészítmény alkalmazásacukorbetegség és abnormális fiziológiás glükózszabályzásemlősszervezetben történő kezelésére szolgáló gyógyszer előállítására. Ó
HU0401612A 2001-10-16 2002-10-15 Pharmaceutical composition suitable for treating diabetes HUP0401612A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32933001P 2001-10-16 2001-10-16
PCT/US2002/032904 WO2003033808A2 (en) 2001-10-16 2002-10-15 Composition and method for treating diabetes

Publications (2)

Publication Number Publication Date
HUP0401612A2 true HUP0401612A2 (hu) 2004-12-28
HUP0401612A3 HUP0401612A3 (en) 2006-04-28

Family

ID=23284879

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401612A HUP0401612A3 (en) 2001-10-16 2002-10-15 Pharmaceutical composition suitable for treating diabetes

Country Status (20)

Country Link
US (2) US20040132644A1 (hu)
EP (1) EP1435995A2 (hu)
JP (1) JP2005506362A (hu)
KR (1) KR20050036865A (hu)
CN (1) CN1723034A (hu)
BR (1) BR0213291A (hu)
CA (1) CA2463769A1 (hu)
CO (2) CO5570658A2 (hu)
CZ (1) CZ2004479A3 (hu)
HU (1) HUP0401612A3 (hu)
IL (1) IL161073A0 (hu)
MA (1) MA27503A1 (hu)
MX (1) MXPA04003526A (hu)
NO (1) NO20042012L (hu)
PE (1) PE20030608A1 (hu)
PL (1) PL370069A1 (hu)
RU (1) RU2004114865A (hu)
SK (1) SK1702004A3 (hu)
WO (1) WO2003033808A2 (hu)
ZA (1) ZA200402261B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275853A1 (en) * 2002-10-24 2004-05-13 Mcgill University Use of ingap for reversing diabetes
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
WO2006096565A2 (en) * 2005-03-04 2006-09-14 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
CA2609667C (en) 2005-05-25 2011-02-22 Curedm, Inc. Human proislet peptide, derivatives and analogs thereof, and methods of using same
EP1840573A1 (en) * 2006-03-27 2007-10-03 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
US8785400B2 (en) * 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
SI2193142T1 (sl) * 2007-08-30 2015-05-29 Curedm Group Holdings, Llc Sestavek in postopek za uporabo proislet peptidov in analogov le-teh
WO2014052611A1 (en) * 2012-09-27 2014-04-03 Levetan Claresa Generation of new pancreatic beta cells
WO2014139182A1 (en) 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
CN104045699A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN104045702A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN104045698B (zh) * 2013-03-15 2019-04-16 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN103305457B (zh) * 2013-06-06 2015-07-08 浙江省医学科学院 一种体外扩增胰岛β细胞的方法
US20160039876A1 (en) * 2014-03-28 2016-02-11 Claresa Levetan Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
WO2017152861A1 (en) * 2016-03-10 2017-09-14 Shenzhen Hightide Biopharmaceutical, Ltd. Conjugates of islet neogenesis peptides and analogs, and methods thereof
US20210196646A1 (en) * 2018-08-15 2021-07-01 Wake Forest University Health Sciences Improved formulations for pancreatic islet encapsulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127624A (en) * 1872-06-04 Improvement in apparatus for elevating water
US4658957A (en) * 1985-01-28 1987-04-21 Abbott Laboratories Utility tray
US6106840A (en) * 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
JP4111539B2 (ja) * 1995-02-22 2008-07-02 イースタン・ヴァージニア・メディカル・スクール・オブ・ザ・メディカル・カレッジ・オブ・ハンプトン・ローズ 膵島新生に関与するｉｎｇａｐタンパク質
US5834590A (en) * 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
ATE299888T1 (de) * 1996-05-03 2005-08-15 Abbott Lab Antiangiogenische peptiden, dafür kodierende polynukleotide und verfahren zur hemmung der angiogenesis
US6090577A (en) * 1997-05-22 2000-07-18 Incyte Pharmaceuticals, Inc. Disease associated acidic protein
US6986994B2 (en) * 2001-01-09 2006-01-17 Gmp Endotherapeutics, Inc. INGAP displacement assays

Also Published As

Publication number Publication date
SK1702004A3 (sk) 2005-03-04
CA2463769A1 (en) 2003-04-24
US20080171704A1 (en) 2008-07-17
CN1723034A (zh) 2006-01-18
WO2003033808A3 (en) 2003-09-18
EP1435995A2 (en) 2004-07-14
WO2003033808A2 (en) 2003-04-24
JP2005506362A (ja) 2005-03-03
BR0213291A (pt) 2004-10-26
PE20030608A1 (es) 2003-08-26
CZ2004479A3 (cs) 2005-01-12
PL370069A1 (en) 2005-05-16
NO20042012L (no) 2004-07-16
MXPA04003526A (es) 2004-07-22
CO5590933A2 (es) 2005-12-30
US20040132644A1 (en) 2004-07-08
HUP0401612A3 (en) 2006-04-28
CO5570658A2 (es) 2005-10-31
IL161073A0 (en) 2004-08-31
MA27503A1 (fr) 2005-09-01
RU2004114865A (ru) 2005-05-27
KR20050036865A (ko) 2005-04-20
ZA200402261B (en) 2004-09-28

Similar Documents

Publication Publication Date Title
HUP0401612A2 (hu) Cukorbetegség kezelésére alkalmas gyógyszerkészítmények
HUP0001153A2 (hu) Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2006023989A3 (en) Gas delivery and monitoring system
HUP0004560A2 (hu) Törést gyógyító PTHrP analógok
BR0009012A (pt) Medicamento para o tratamento de diabete
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
HUP9603237A2 (hu) (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzizotiazol-2-il)-butil]-amino-metil}-kromán kristályos hidrokloridja, eljárás előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
ATE141792T1 (de) Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson- syndromen
MXPA02006679A (es) Composicion farmaceutica.
IL173399A (en) Circular dna molecules, processes for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medical products for producing recombinant proteins in vivo
HUP0400988A2 (hu) Kombinált NEP/MP-gátló aktivitással rendelkező vegyületek felhasználása gyógyszerek előállítására
HUP0000088A2 (hu) N-Szubsztituált azaheterociklusos vegyületek, eljárás előállításukra, valamint ezeket a vegyületeket tartalmazó gyógyszerkészítmények
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
GR3027620T3 (en) Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
MY103757A (en) Apparatus for the delivery of substances, processes for the production thereof and use thereof
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
SI0820303T1 (en) PEPTIDE p277 ANALOGS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR TREATMENT OR DIAGNOSIS OF DIABETES
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
HK1079549A1 (en) Muteins of placental growth factor type 1, preparation method and application thereof
ATE198278T1 (de) Verwendung von sulodexid und von arzneimitteln, die dieses enthalten, zur behandlung der diabetischen nephropathie
DE60208180D1 (de) Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung
ATE281159T1 (de) Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz
HUP0400662A2 (hu) A hosszú PTX3-pentraxin és a női termékenység
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
AU3739500A (en) Protease resistant flint analogs

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees